<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Median Technologies — News on 6ix</title>
<link>https://6ix.com/company/median-technologies</link>
<description>Latest news and press releases for Median Technologies on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 23 Apr 2026 15:45:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/median-technologies" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d52b58beedb30cb6f6b368.webp</url>
<title>Median Technologies</title>
<link>https://6ix.com/company/median-technologies</link>
</image>
<item>
<title>Median Technologies Reports Full-Year 2025 Financial Results and Provides Key Q1 2026 Business Highlights</title>
<link>https://6ix.com/company/median-technologies/news/median-technologies-reports-full-year-2025-financial-results-and-provides-key-q1-2026-business-highlights-1</link>
<guid isPermaLink="true">https://6ix.com/company/median-technologies/news/median-technologies-reports-full-year-2025-financial-results-and-provides-key-q1-2026-business-highlights-1</guid>
<pubDate>Thu, 23 Apr 2026 15:45:00 GMT</pubDate>
<description>SOPHIA ANTIPOLIS, France, April 23, 2026--Regulatory News: Median Technologies (FR0011049824, ALMDT, "Median" or the "Company"), developer of eyonis®, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnosis, and a globally leading provider of AI-powered and central imaging services for oncology drug developers, today reported its 2025 consolidated annual financial results, and provided key business highlights (unaudited) for the first quarte</description>
</item>
<item>
<title>Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of March 31, 2026</title>
<link>https://6ix.com/company/median-technologies/news/median-technologies-disclosure-of-total-number-of-voting-rights-and-number-of-shares-in-the-capital-as-of-march-31-2026-1</link>
<guid isPermaLink="true">https://6ix.com/company/median-technologies/news/median-technologies-disclosure-of-total-number-of-voting-rights-and-number-of-shares-in-the-capital-as-of-march-31-2026-1</guid>
<pubDate>Tue, 07 Apr 2026 15:45:00 GMT</pubDate>
<description>SOPHIA ANTIPOLIS, France, April 07, 2026--Regulatory News: Median Technologies (Paris:ALMDT):</description>
</item>
<item>
<title>Median Technologies Achieves ISO 13485:2016 Certification for eyonis® Medical Device Quality Management System</title>
<link>https://6ix.com/company/median-technologies/news/median-technologies-achieves-iso-134852016-certification-for-eyonisr-medical-device-quality-management-system</link>
<guid isPermaLink="true">https://6ix.com/company/median-technologies/news/median-technologies-achieves-iso-134852016-certification-for-eyonisr-medical-device-quality-management-system</guid>
<pubDate>Wed, 18 Mar 2026 16:45:00 GMT</pubDate>
<description>SOPHIA-ANTIPOLIS, France, March 18, 2026--Regulatory News: Median Technologies (FR0011049824, ALMDT, "Median" or the "Company"), developer of eyonis®, a suite of artificial intelligence (AI)-powered Software as a Medical Device (SaMD) solutions for early cancer diagnosis, and a globally leading provider of AI-based image analyses and central imaging services for oncology drug developers, today announced it has achieved the globally recognized ISO 13485:2016 certification for its Quality Manageme</description>
</item>
<item>
<title>Median Technologies Meets the Eligibility Conditions for the PEA-PME Scheme</title>
<link>https://6ix.com/company/median-technologies/news/median-technologies-meets-the-eligibility-conditions-for-the-pea-pme-scheme</link>
<guid isPermaLink="true">https://6ix.com/company/median-technologies/news/median-technologies-meets-the-eligibility-conditions-for-the-pea-pme-scheme</guid>
<pubDate>Fri, 13 Mar 2026 16:45:00 GMT</pubDate>
<description>SOPHIA ANTIPOLIS, France, March 13, 2026--Regulatory News: Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible, "Median" or the "Company"), developer of eyonis®, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnosis, and a globally leading provider of AI-based image analyses and central imaging services for oncology drug developers, today confirms its eligibility for the PEA-PME investment scheme, in accordance with the provi</description>
</item>
<item>
<title>Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of February 28, 2026</title>
<link>https://6ix.com/company/median-technologies/news/median-technologies-disclosure-of-total-number-of-voting-rights-and-number-of-shares-in-the-capital-as-of-february-28-2026</link>
<guid isPermaLink="true">https://6ix.com/company/median-technologies/news/median-technologies-disclosure-of-total-number-of-voting-rights-and-number-of-shares-in-the-capital-as-of-february-28-2026</guid>
<pubDate>Mon, 09 Mar 2026 16:45:00 GMT</pubDate>
<description>SOPHIA ANTIPOLIS, France, March 09, 2026--Regulatory News: Median Technologies (Paris:ALMDT):</description>
</item>
<item>
<title>Median Technologies to Showcase eyonis® LCS, Its AI/ML-based Software as a Medical Device for Lung Cancer Screening, at the European Congress of Radiology</title>
<link>https://6ix.com/company/median-technologies/news/median-technologies-to-showcase-eyonisr-lcs-its-aiml-based-software-as-a-medical-device-for-lung-cancer-screening-at-the-european-congress-of-radiology</link>
<guid isPermaLink="true">https://6ix.com/company/median-technologies/news/median-technologies-to-showcase-eyonisr-lcs-its-aiml-based-software-as-a-medical-device-for-lung-cancer-screening-at-the-european-congress-of-radiology</guid>
<pubDate>Mon, 02 Mar 2026 16:45:00 GMT</pubDate>
<description>SOPHIA ANTIPOLIS, France, March 02, 2026--Regulatory News: Median Technologies (FR0011049824, ALMDT, "Median" or the "Company"), developer of eyonis®, a suite of artificial intelligence (AI)-powered Software as Medical Devices (SaMDs) for early cancer diagnosis and a global leader in AI-based image analysis and central imaging services for oncology drug development, today announced that it will feature eyonis® LCS at the European Congress of Radiology (ECR) 2026 in Vienna, March 4–6, 2026.</description>
</item>
<item>
<title>Median Technologies to present at the TD Cowen 46th Annual Health Care Conference</title>
<link>https://6ix.com/company/median-technologies/news/median-technologies-to-present-at-the-td-cowen-46th-annual-health-care-conference</link>
<guid isPermaLink="true">https://6ix.com/company/median-technologies/news/median-technologies-to-present-at-the-td-cowen-46th-annual-health-care-conference</guid>
<pubDate>Fri, 27 Feb 2026 17:38:00 GMT</pubDate>
<description>SOPHIA ANTIPOLIS, France, February 27, 2026--Regulatory News: Median Technologies (FR0011049824, ALMDT, "Median" or the "Company"), developer of eyonis®, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnosis, and a globally leading provider of AI-based image analyses and central imaging services for oncology drug developers announced today that it will participate in TD Cowen’s 46th Annual Health Care Conference, taking place March 2-4, 20</description>
</item>
<item>
<title>Median Technologies to Host Webcasts Highlighting Strategic Advances Driving U.S. Deployment of eyonis® LCS</title>
<link>https://6ix.com/company/median-technologies/news/median-technologies-to-host-webcasts-highlighting-strategic-advances-driving-us-deployment-of-eyonisr-lcs</link>
<guid isPermaLink="true">https://6ix.com/company/median-technologies/news/median-technologies-to-host-webcasts-highlighting-strategic-advances-driving-us-deployment-of-eyonisr-lcs</guid>
<pubDate>Mon, 23 Feb 2026 16:45:00 GMT</pubDate>
<description>SOPHIA ANTIPOLIS, France, February 23, 2026--Regulatory News: Median Technologies (FR0011049824, ALMDT, "Median" or the "Company"), developer of eyonis®, a suite of artificial intelligence (AI) powered Software as Medical Devices (SaMD) for early cancer diagnosis, and a globally leading provider of AI-based image analyses and central imaging services for oncology drug developers, today announced that it will host two webcasts on February 26, 2026.</description>
</item>
<item>
<title>FDA Clearance Sets Stage for U.S. Commercialization of eyonis® LCS Software as a Medical Device for Lung Cancer Screening; Oran Muduroglu Appointed President of Median eyonis Inc.</title>
<link>https://6ix.com/company/median-technologies/news/fda-clearance-sets-stage-for-us-commercialization-of-eyonisr-lcs-software-as-a-medical-device-for-lung-cancer-screening-oran-muduroglu-appointed-president-of-median-eyonis-inc-1</link>
<guid isPermaLink="true">https://6ix.com/company/median-technologies/news/fda-clearance-sets-stage-for-us-commercialization-of-eyonisr-lcs-software-as-a-medical-device-for-lung-cancer-screening-oran-muduroglu-appointed-president-of-median-eyonis-inc-1</guid>
<pubDate>Wed, 18 Feb 2026 16:45:00 GMT</pubDate>
<description>SOPHIA ANTIPOLIS, France, February 18, 2026--Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260218440005/en/</description>
</item>
<item>
<title>Median Technologies Announces Collaboration With Tempus to Expand Access to eyonis® LCS Software as a Medical Device in the United States</title>
<link>https://6ix.com/company/median-technologies/news/median-technologies-announces-collaboration-with-tempus-to-expand-access-to-eyonisr-lcs-software-as-a-medical-device-in-the-united-states-1</link>
<guid isPermaLink="true">https://6ix.com/company/median-technologies/news/median-technologies-announces-collaboration-with-tempus-to-expand-access-to-eyonisr-lcs-software-as-a-medical-device-in-the-united-states-1</guid>
<pubDate>Thu, 12 Feb 2026 21:05:00 GMT</pubDate>
<description>SOPHIA ANTIPOLIS, France & CHICAGO, February 12, 2026--Regulatory News: Median Technologies (FR0011049824, ALMDT, "Median" or the "Company"), developer of eyonis®, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnosis, and a provider of AI-enhanced and central imaging services for oncology drug developers, today announced its non-exclusive distribution agreement with Tempus AI, Inc. (NASDAQ: TEM) a technology company leading the adoption o</description>
</item>
<item>
<title>Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of January 31, 2026</title>
<link>https://6ix.com/company/median-technologies/news/median-technologies-disclosure-of-total-number-of-voting-rights-and-number-of-shares-in-the-capital-as-of-january-31-2026-1</link>
<guid isPermaLink="true">https://6ix.com/company/median-technologies/news/median-technologies-disclosure-of-total-number-of-voting-rights-and-number-of-shares-in-the-capital-as-of-january-31-2026-1</guid>
<pubDate>Wed, 11 Feb 2026 16:45:00 GMT</pubDate>
<description>SOPHIA ANTIPOLIS, France, February 11, 2026--Regulatory News: Median Technologies (Paris:ALMDT):</description>
</item>
<item>
<title>Median Technologies Receives FDA 510(k) Clearance for eyonis® LCS, the First AI Tech-Based Detection and Diagnosis Device for Lung Cancer Screening</title>
<link>https://6ix.com/company/median-technologies/news/median-technologies-receives-fda-510k-clearance-for-eyonisr-lcs-the-first-ai-tech-based-detection-and-diagnosis-device-for-lung-cancer-screening-1</link>
<guid isPermaLink="true">https://6ix.com/company/median-technologies/news/median-technologies-receives-fda-510k-clearance-for-eyonisr-lcs-the-first-ai-tech-based-detection-and-diagnosis-device-for-lung-cancer-screening-1</guid>
<pubDate>Mon, 09 Feb 2026 06:00:00 GMT</pubDate>
<description>SOPHIA ANTIPOLIS, France, February 09, 2026--Regulatory News: Median Technologies (FR0011049824, ALMDT, "Median" or the "Company"), developer of eyonis®, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnosis, and a globally leading provider of AI-based image analyses and central imaging services for oncology drug developers, today announced it has received FDA 510(k) clearance for eyonis® LCS, its AI/ML-powered computer-aided detection and</description>
</item>
<item>
<title>Median Technologies Reports Landmark 2025 Performance With Major Regulatory and Commercial Milestones Ahead in 2026</title>
<link>https://6ix.com/company/median-technologies/news/median-technologies-reports-landmark-2025-performance-with-major-regulatory-and-commercial-milestones-ahead-in-2026-1</link>
<guid isPermaLink="true">https://6ix.com/company/median-technologies/news/median-technologies-reports-landmark-2025-performance-with-major-regulatory-and-commercial-milestones-ahead-in-2026-1</guid>
<pubDate>Mon, 19 Jan 2026 06:00:00 GMT</pubDate>
<description>SOPHIA ANTIPOLIS, France, January 19, 2026--Regulatory News: Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible, "Median" or the "Company"), manufacturer of eyonis®, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnosis, and a globally leading provider of AI-based image analyses and central imaging services for oncology drug developers, releases today its 2025 key business results (including unaudited figures) and provides a</description>
</item>
<item>
<title>Median Technologies: H1 2026 Financial Communication Calendar</title>
<link>https://6ix.com/company/median-technologies/news/median-technologies-h1-2026-financial-communication-calendar-1</link>
<guid isPermaLink="true">https://6ix.com/company/median-technologies/news/median-technologies-h1-2026-financial-communication-calendar-1</guid>
<pubDate>Wed, 14 Jan 2026 16:45:00 GMT</pubDate>
<description>SOPHIA ANTIPOLIS, France, January 14, 2026--Regulatory News: Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible, "Median" or the "Company"), manufacturer of eyonis®, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnosis, and a globally leading provider of AI-based image analyses and central imaging services for oncology drug developers, announces today its H1 2026 financial communication calendar.</description>
</item>
<item>
<title>Half Year Median Technologies Liquidity Contract Statement</title>
<link>https://6ix.com/company/median-technologies/news/half-year-median-technologies-liquidity-contract-statement-1</link>
<guid isPermaLink="true">https://6ix.com/company/median-technologies/news/half-year-median-technologies-liquidity-contract-statement-1</guid>
<pubDate>Wed, 07 Jan 2026 16:45:00 GMT</pubDate>
<description>SOPHIA ANTIPOLIS, France, January 07, 2026--Regulatory News: Under the liquidity contract entrusted by Median Technologies (FR0011049824, ALMDT, PEA/SME eligible, "Median" or "the Company") to TP ICAP (Europe), the following resources were listed in the liquidity account as of December 31, 2025:</description>
</item>
<item>
<title>Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of December 31, 2025</title>
<link>https://6ix.com/company/median-technologies/news/median-technologies-disclosure-of-total-number-of-voting-rights-and-number-of-shares-in-the-capital-as-of-december-31-2025-1</link>
<guid isPermaLink="true">https://6ix.com/company/median-technologies/news/median-technologies-disclosure-of-total-number-of-voting-rights-and-number-of-shares-in-the-capital-as-of-december-31-2025-1</guid>
<pubDate>Mon, 05 Jan 2026 16:45:00 GMT</pubDate>
<description>SOPHIA ANTIPOLIS, France, January 05, 2026--Regulatory News: Median Technologies (Paris:ALMDT):</description>
</item>
<item>
<title>Median Technologies Partners With Leading U.S. Healthcare Company to Bring eyonis® LCS to Patients Across the U.S. and Europe</title>
<link>https://6ix.com/company/median-technologies/news/median-technologies-partners-with-leading-us-healthcare-company-to-bring-eyonisr-lcs-to-patients-across-the-us-and-europe-1</link>
<guid isPermaLink="true">https://6ix.com/company/median-technologies/news/median-technologies-partners-with-leading-us-healthcare-company-to-bring-eyonisr-lcs-to-patients-across-the-us-and-europe-1</guid>
<pubDate>Mon, 08 Dec 2025 16:45:00 GMT</pubDate>
<description>SOPHIA ANTIPOLIS, France, December 08, 2025--Regulatory News: Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible, "Median" or the "Company"), manufacturer of eyonis® , a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnosis, and a globally leading provider of AI-based image analyses and central imaging services for oncology drug developers, today announced the signing of a non-exclusive global commercial distribution agreement</description>
</item>
<item>
<title>Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of November 30, 2025</title>
<link>https://6ix.com/company/median-technologies/news/median-technologies-disclosure-of-total-number-of-voting-rights-and-number-of-shares-in-the-capital-as-of-november-30-2025-1</link>
<guid isPermaLink="true">https://6ix.com/company/median-technologies/news/median-technologies-disclosure-of-total-number-of-voting-rights-and-number-of-shares-in-the-capital-as-of-november-30-2025-1</guid>
<pubDate>Wed, 03 Dec 2025 16:45:00 GMT</pubDate>
<description>SOPHIA ANTIPOLIS, France, December 03, 2025--Regulatory News: Median Technologies (Paris:ALMDT):</description>
</item>
<item>
<title>Median Technologies to Showcase AI-Powered Software as a Medical Device eyonis® LCS for Lung Cancer Screening at the RSNA 2025 Annual Meeting</title>
<link>https://6ix.com/company/median-technologies/news/median-technologies-to-showcase-ai-powered-software-as-a-medical-device-eyonisr-lcs-for-lung-cancer-screening-at-the-rsna-2025-annual-meeting-1</link>
<guid isPermaLink="true">https://6ix.com/company/median-technologies/news/median-technologies-to-showcase-ai-powered-software-as-a-medical-device-eyonisr-lcs-for-lung-cancer-screening-at-the-rsna-2025-annual-meeting-1</guid>
<pubDate>Tue, 25 Nov 2025 16:45:00 GMT</pubDate>
<description>SOPHIA ANTIPOLIS, France, November 25, 2025--Regulatory News: Median Technologies (FR0011049824, ALMDT, PEA/SME eligible, "Median" or "The Company"), manufacturer of eyonis®, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnosis, and a globally leading provider of AI-based image analyses and central imaging services for oncology drug developers, today announced that it will attend the Radiological Society of North America (RSNA) 2025 Annua</description>
</item>
<item>
<title>Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of October 31, 2025</title>
<link>https://6ix.com/company/median-technologies/news/median-technologies-disclosure-of-total-number-of-voting-rights-and-number-of-shares-in-the-capital-as-of-october-31-2025-1</link>
<guid isPermaLink="true">https://6ix.com/company/median-technologies/news/median-technologies-disclosure-of-total-number-of-voting-rights-and-number-of-shares-in-the-capital-as-of-october-31-2025-1</guid>
<pubDate>Thu, 13 Nov 2025 16:45:00 GMT</pubDate>
<description>SOPHIA ANTIPOLIS, France, November 13, 2025--Regulatory News: Median Technologies (Paris:ALMDT):</description>
</item>
</channel>
</rss>